[1]刘 灿,陈丹杰,余军林,等.晚期食管鳞癌患者血清sPD-L1与组织PD-L1的表达及与预后的关系[J].郑州大学学报(医学版),2019,(04):500-503.[doi:10.13705/j.issn.1671-6825.2018.12.039]
 LIU Can,CHEN Danjie,YU Junlin,et al.Detection of serum sPD-L1 and tissue PD-L1 in patients with advanced esophageal squamous cell carcinoma and prognostic value[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2019,(04):500-503.[doi:10.13705/j.issn.1671-6825.2018.12.039]
点击复制

晚期食管鳞癌患者血清sPD-L1与组织PD-L1的表达及与预后的关系()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2019年04期
页码:
500-503
栏目:
食管癌研究
出版日期:
2019-07-20

文章信息/Info

Title:
Detection of serum sPD-L1 and tissue PD-L1 in patients with advanced esophageal squamous cell carcinoma and prognostic value
作者:
刘 灿陈丹杰余军林孟祥瑞辛 道刘德恩王 峰
郑州大学第一附属医院肿瘤科 郑州 450052
Author(s):
LIU CanCHEN DanjieYU JunlinMENG XiangruiXIN DaoLIU De'enWANG Feng
Department of Oncology,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052
关键词:
食管鳞癌 程序性死亡配体1 预后
Keywords:
esophageal squamous cell carcinoma programmed cell death ligand 1 prognosis
分类号:
R735.1
DOI:
10.13705/j.issn.1671-6825.2018.12.039
摘要:
目的:探讨血清可溶性程序性死亡配体1(sPD-L1)水平、组织PD-L1的表达对晚期食管鳞癌的预后判断价值。方法:收集晚期食管鳞癌患者127例,健康对照71名,ELISA法测定健康对照组及食管鳞癌组化疗前血清sPD-L1水平,同时检测炎性指标NLR、SII水平; 免疫组化法测定食管鳞癌组织中PD-L1的表达,分析血清sPD-L1与组织PD-L1及NLR、SII的关系; Kaplan-Meier法和Cox回归分析晚期食管鳞癌患者预后影响因素。结果:食管鳞癌组血清sPD-L1、NLR、SII水平均高于健康对照组(P均<0.05)。食管鳞癌患者血清sPD-L1水平与组织PD-L1表达无关(P=0.619),但与炎性指标NLR、SII有关(P均<0.05)。Kaplan-Meier法分析结果表明,sPD-L1水平、PD-L1表达和肿瘤部位与晚期食管鳞癌患者的预后有关(P均<0.05)。Cox回归分析表明sPD-L1与PD-L1是晚期食管鳞癌预后的独立影响因素,高sPD-L1水平、PD-L1阳性的患者死亡风险增加(HR=1.533,95%CI=1.063-2.211; HR=1.703,95%CI=1.058-2.739)。结论:血清sPD-L1与组织PD-L1可用于晚期食管鳞癌患者的预后判定。
Abstract:
Aim:To explore the prognostic value of serum soluble programmed cell death ligand 1(sPD-L1)and tissue PD-L1 expression in advanced esophageal squamous cell carcinoma(ESCC).Methods:A total of 127 patients with advanced ESCC and 71 healthy volunteers(control group)were collected.Serum sPD-L1 in the control group and ESCC group was measured by ELISA.Meanwhile, NLR and SII,the inflammatory indexes in the two groups were calculated.The expression of PD-L1 in ESCC tissue was detected by immunohistochemistry.The relationship between serum sPD-L1 and tissue PD-L1,NLR,SII was analyzed. Kaplan-Meier analysis and Cox regression analysis were used to determine the risk factors on the prognosis.Results:Serum sPD-L1,NLR and SII in ESCC group were higher than those in control group(P<0.05). The level of sPD-L1 in ESCC was not associated with the expression of PD-L1(P=0.619), but it was associated with NLR and SII(P<0.05). Kaplan-Meier analysis indicated that sPD-L1, PD-L1 and tumor sites were related to the prognosis of advanced ESCC(P<0.05). Cox regression analysis showed that sPD-L1 and PD-L1 were independent prognostic factors for advanced ESCC, and high sPD-L1 level or PD-L1 positive patients had a significant increased risk of death(HR=1.533,95%CI=1.063-2.211; HR=1.703,95%CI=1.058-2.739).Conclusion:Serum sPD-L1 level and tissue PD-L1 expression can be prognostic indicators for patients with advanced ESCC.

参考文献/References:

[1] SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics, 2017[J].CA Cancer J Clin,2017,67(1):7
[2] GOTWALS P,CAMERON S,CIPOLLETTA D,et al.Prospects for combining targeted and conventional cancer therapy with immunotherapy[J].Nat Rev Cancer,2017,17(5):286
[3] BOUSSIOTIS VA.Molecular and biochemical aspects of the PD-1 checkpoint pathway[J].N Engl J Med,2016,375(18):1767
[4] ZHANG G,HOU J,SHI J,et al.Soluble CD276(B7-H3)is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum[J].Immunology,2008,123(4):538
[5] DE LA FUENTE H, CIBRIÁN D, SÁNCHEZ-MADRID F. Immunoregulatory molecules are master regulators of inflammation during the immune response[J]. FEBS Lett,2012,586(18):2897
[6] OKUMA Y,HOSOMI Y,NAKAHARA Y,et al.High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer[J].Lung Cancer,2017,104:1
[7] FINKELMEIER F,CANLI Ö,TAL A,et al.High levels of the soluble programmed death-ligand(sPD-L1)identify hepatocellular carcinoma patients with a poor prognosis[J].Eur J Cancer,2016,59:152
[8] ZHU YM,LI MH,MU DB,et al.CD8+/FOXP3+ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer[J].Oncotarget,2016,7(44):71455
[9] ZHANG J,GAO J,LI YY,et al.Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics[J].Thorac Cancer,2015,6(4):534
[10]AZIZ MH, SIDERAS K, AZIZ NA, et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on Bilirubin levels: a retrospective multicenter cohort study[J]. Ann Surg,2019,270(1):139
[11]HA H,NAM AR,BANG JH,et al.Soluble programmed death-ligand 1(sPDL1)and neutrophil-to-lymphocyte ratio(NLR)predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy[J].Oncotarget,2016,7(47):76604
[12]KRUGER S,LEGENSTEIN ML,ROESGEN VA,et al.Serum levels of soluble programmed death protein 1(sPD-1)and soluble programmed death ligand 1(sPD-L1)in advanced pancreatic cancer[J].Oncoimmunology,2017,6(5):e1310358
[13]JIN JJ,SI JM,LIU YH,et al.Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy[J].Respir Res,2018,19(1):197
[14]HARABUCHI Y,TAKAHARA M,KISHIBE K,et al.Nasal natural killer(NK)/T-cell lymphoma: clinical, histological, virological, and genetic features[J].Int J Clin Oncol,2009,14(3):181
[15]HAN XE,GU YK,LI SL,et al.Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma[J].J Cancer Res Clin Oncol,2019,145(2):303
[16]DONG YA,SUN Q,ZHANG XW.PD-1 and its ligands are important immune checkpoints in cancer[J].Oncotarget,2017,8(2):2171
[17]ZHOU J,MAHONEY KM,GIOBBIE-HURDER A,et al.Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade[J].Cancer Immunol Res,2017,5(6):480
[18]SUNSHINE J, TAUBE JM. PD-1/PD-L1 inhibitors[J]. Curr Opin Pharmacol,2015,23:32
[19]QU HX,ZHAO LP,ZHAN SH,et al.Clinicopathological and prognostic significance of programmed cell death ligand 1(PD-L1)expression in patients with esophageal squamous cell carcinoma: a meta-analysis[J].J Thorac Dis,2016,8(11):3197
[20]KIM R,KEAM B,KWON D,et al.Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma[J].World J Gastroenterol,2016,22(37):8389
[21]关嵩,王军,刘月平,等.食管鳞癌组织PD-L1表达临床意义[J].中华肿瘤防治杂志,2018,25(11):778
[22]JIANG YB,LO AW,WONG A,et al.Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma[J].Oncotarget,2017,8(18):30175

相似文献/References:

[1]魏攀,李杰,王莉莉,等.转染杜氏盐藻1433基因对食管鳞癌EC9706细胞Bcl2和Caspase9蛋白表达的影响*[J].郑州大学学报(医学版),2010,(01):4.
 WEI Pan,LI Jie,WANG Lili,et al.Expression of Bcl2 and Caspase9 proteins of EC9706 cell transfected 1433 gene of Dunaliella salina[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2010,(04):4.
[2]郑乃刚)),阎爱华),吴景兰),等.食管鳞癌的肿瘤干细胞标志[J].郑州大学学报(医学版),2010,(01):27.
 ZHENG Naigang),YAN Aihua),WU Jinglan),et al.Cancer stem cell biomarker in human esophageal squamous cell carcinoma tissue and Eca109 and EC9706 cells[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2010,(04):27.
[3]侯桂琴),贝维娟),杨帅),等.食管鳞癌细胞中PTEN基因表达水平及突变位点分析*[J].郑州大学学报(医学版),2013,(05):577.
 HOU Guiqin),BEI Weijuan),YANG Shuai),et al.Expression and mutation sites analysis of PTEN gene in esophageal squamous cell carcinoma cells[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2013,(04):577.
[4]卢红△,王建军,周芳.食管鳞癌组织中磷酸化表皮生长因子受体和Akt蛋白的表达*[J].郑州大学学报(医学版),2015,(01):5.
 LU Hong,WANG Jianjun,ZHOU Fang.Expressions of pEGFR and pAkt proteins in esophageal squamous cell carcinoma tissue[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2015,(04):5.
[5]吕 双),宋 昕),赵学科),等.食管鳞癌肿瘤最大长径与浸润深度(T分期)的关系*[J].郑州大学学报(医学版),2017,(05):522.[doi:10.13705/j.issn.1671-6825.2017.05.002]
 LYU Shuang),SONG Xin),ZHAO Xueke),et al.Relationship between the maximum tumor length and invasion depth(T Stage)in esophageal squamous cell carcinoma[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2017,(04):522.[doi:10.13705/j.issn.1671-6825.2017.05.002]
[6]凡 丞,鲁照明,张幸丽,等.食管鳞癌Eca109细胞中PI3K/AKT/mTOR信号通路对LSD1的调控作用*[J].郑州大学学报(医学版),2017,(05):531.[doi:10.13705/j.issn.1671-6825.2017.05.004]
 FAN Cheng,LU Zhaoming,ZHANG Xingli,et al.Regulation effects of PI3K/AKT/mTOR signaling pathway on LSD1 in Eca109 cells[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2017,(04):531.[doi:10.13705/j.issn.1671-6825.2017.05.004]
[7]张幸丽,侯桂琴,凡 丞,等.食管鳞癌细胞中LSD1通过与Notch靶基因启动子结合调控Notch通路相关蛋白表达*[J].郑州大学学报(医学版),2017,(06):672.[doi:10.13705/j.issn.1671-6825.2017.06.003]
 ZHANG Xingli,HOU Guiqin,FAN Cheng,et al.LSD1 regulates expression of related proteins of Notch pathway through combining promotor of target gene of Notch in esophageal squamous cell carcinoma cells[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2017,(04):672.[doi:10.13705/j.issn.1671-6825.2017.06.003]
[8]张 乐),李庆华),杨 璐),等.DZNep对裸鼠食管鳞癌移植瘤生长的抑制作用[J].郑州大学学报(医学版),2018,(01):17.[doi:10.13705/j.issn.1671-6825.2017.02.060]
 ZHANG Le),LI Qinghua),YANG Lu),et al.Inhibition effects of DZNep on growth of esophageal squamous cell carcinoma xenograft in nude mice[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2018,(04):17.[doi:10.13705/j.issn.1671-6825.2017.02.060]
[9]刘怡文,孙 蔚,齐义军,等.食管鳞癌组织中GSK3β表达的临床意义[J].郑州大学学报(医学版),2018,(01):21.[doi:10.13705/j.issn.1671-6825.2016.12.060]
 LIU Yiwen,SUN Wei,QI Yijun,et al.Clinical significance of GSK3β expression in esophageal squamous cell carcinoma tissue[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2018,(04):21.[doi:10.13705/j.issn.1671-6825.2016.12.060]
[10]陈丹杰,孟祥瑞,刘 灿,等.食管鳞癌淋巴结包膜外侵犯对预后相关因素的影响[J].郑州大学学报(医学版),2018,(03):276.[doi:10.13705/j.issn.1671-6825.2017.09.068]
 CHEN Danjie,MENG Xiangrui,LIU Can,et al.The influence of lymph nodes extranodal extension of esophageal squamous cell carcinoma on the prognostic factors[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2018,(04):276.[doi:10.13705/j.issn.1671-6825.2017.09.068]

备注/Memo

备注/Memo:
【作者简介】王峰,通信作者,男,1975年10月生,博士,副教授,研究方向:消化道肿瘤基础与临床,E-mail:fengw010@163.com
更新日期/Last Update: 2019-07-20